Cointime

ArriVent Biopharma

company

About

ArriVent is dedicated to accelerating the global development of innovative biopharmaceutical products.

  • 11 - 50

Highlights

Total Funding Amount
$150M
Funding Rounds
2
Investors
2

Details

Last Funding Type
Series A
Last Funding Money Raised
$69M
Industries
Biotechnology,Pharmaceutical
Founded date
Jan 1, 2021
Number Of Employee
11 - 50
Operating Status
Active

ArriVent is dedicated to accelerating the global development of innovative biopharmaceutical products.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
2
$150M
ArriVent Biopharma has raised a total of $150M in funding over 2 rounds. Their latest funding was raised on Feb 15, 2022 from a Series A round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Feb 15, 2022 Series A $69M 2 — — Detail
Jun 30, 2021 Series A $81M 2 — — Detail

Investors

Number of Lead Investors
Number of Investors
—
2
ArriVent Biopharma is funded by 2 investors. Lyra Capital and Lilly Asia Ventures are the most recent investors.
Investor Name Lead Investor Funding Round
Lyra Capital — Series A
Lilly Asia Ventures — Series A
Cointime
เนื้อหา
บริษัท